
    
      To evaluate the safety and tolerability of ADXS-503, administered as monotherapy in Part A
      and in combination with pembrolizumab in Part B, and to determine the maximum tolerated dose
      (MTD) or maximum administered dose (MAD). As well, to characterize the preliminary anti-tumor
      activity of ADXS-503, administered in combination with pembrolizumab in Part C, per RECIST
      v1.1.
    
  